P.J. Devereaux, MD is a cardiologist with a master's degree in clinical epidemiology and a PhD in clinical epidemiology. He is the Director of McMaster University's Division of Perioperative Care. He is the Scientific Leader of the Population Health Research Institute's Anesthesiology, Perioperative Medicine, and Surgical Research Group. In this video, he discusses PeriOperative ISchemic Evaluation-3 Trial (POISE-3). Description in detail:The POISE-3 experiment is a multicenter, international, non-inferiority randomized controlled trial of tranexamic acid (TXA) against placebo and, utilizing a partial factorial design, a perioperative hypotension-avoidance versus hypertension-avoidance strategy. The primary goal of the study is to determine whether TXA is superior to placebo in terms of the occurrence of life-threatening, major, and critical organ bleeding, and non-inferior to placebo in terms of the occurrence of major arterial and venous thrombotic events; and the impact of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of vascular death and major vascular events in patients who are followed for 30 days after noncardiac surgery. - Cardiology - 718_600c9efaa3c99

Podcast P.J. Devereaux, MD @PHRIresearch @MacDeptMed #POISE3 Phase III POISE-3 Trial

Podcast P.J. Devereaux, MD @PHRIresearch @MacDeptMed #POISE3 Phase III POISE-3 Trial

5 months
83 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

P.J. Devereaux, MD is a cardiologist with a master's degree in clinical epidemiology and a PhD in clinical epidemiology. He is the Director of McMaster University's Division of Perioperative Care. He is the Scientific Leader of the Population Health Research Institute's Anesthesiology, Perioperative Medicine, and Surgical Research Group. In this video, he discusses PeriOperative ISchemic Evaluation-3 Trial (POISE-3).

 

Description in detail:

The POISE-3 experiment is a multicenter, international, non-inferiority randomized controlled trial of tranexamic acid (TXA) against placebo and, utilizing a partial factorial design, a perioperative hypotension-avoidance versus hypertension-avoidance strategy. The primary goal of the study is to determine whether TXA is superior to placebo in terms of the occurrence of life-threatening, major, and critical organ bleeding, and non-inferior to placebo in terms of the occurrence of major arterial and venous thrombotic events; and the impact of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of vascular death and major vascular events in patients who are followed for 30 days after noncardiac surgery.

Up Next Autoplay